Results 251 to 260 of about 38,769 (305)

Dietary interventions in acute kidney injury: From molecular mechanism to clinical trials

Experimental Physiology, EarlyView.
Abstract Ageing impairs renal resilience with an elevated risk of frequent and harmful acute kidney injury (AKI) that causes substantial morbidity and mortality among hospitalized patients. Since different damaging stimuli at the molecular, cellular and functional level contribute to this loss in kidney function, AKI's pathophysiology is heterogeneous ...
Felix C. Koehler, Pedro Rojas‐Morales, Roman‐Ulrich Müller   +2 more
wiley   +1 more source

Beyond Glycemia: Pharmacology-Driven Ketogenesis and Euglycemic DKA with SGLT2 Inhibitors-A Practical Review for Acute Care. [PDF]

J Pers Med
Meco M, Agosteo E, Zulli P, Nisi F, Giustiniano E.   +4 more
europepmc   +1 more source

Cardiac remodelling in type 2 diabetes: Pathophysiological mechanisms and opportunities for multiscale computational modelling and simulation

The Journal of Physiology, EarlyView.
Abstract figure legend Overview of multiscale cardiac remodelling in type 2 diabetes and how to model and simulate these changes using a human‐based, multiscale computational framework. Cardiac remodelling in type 2 diabetes occurs at ionic channel, protein, cellular, tissue and whole‐organ level, affecting the electrophysiological function, mechanical
Ambre Bertrand, Jakub Tomek, Blanca Rodriguez   +2 more
wiley   +1 more source

Use of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Heart Failure Without Diabetes. [PDF]

Cureus
Jiron Vindas J, Lopez Mendoza MJ, Valle Mena MJ, Salazar Estrada MA, Ulloa A, Contreras Figueroa N.   +5 more
europepmc   +1 more source

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 168-177, July 2026.
Target trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Shih‐Hsuan Lin, Jia‐Jin Chen, Ching‐Chung Hsiao, Yu‐Wei Fang, Meng‐Ting Chen, Ming‐Hsien Tsai, Huang‐Yu Yang   +6 more
wiley   +1 more source

Unexpected therapeutic scenarios: initiating SGLT2 inhibitors in de novo heart failure without echocardiography. [PDF]

Eur Heart J Suppl
Di Odoardo LAF, D'Elia E, Sciatti E, Zucchetti O, Fazzini L, D'Isa S, Senni M.   +6 more
europepmc   +1 more source

Repurposing SGLT2 Inhibitors for Cirrhotic Ascites: From Mechanistic Research to Clinical Exploration. [PDF]

J Clin Transl Hepatol
Gao Y, Gao Y, Ji D, Hu Z.
europepmc   +1 more source

Real-World Effectiveness of SGLT2 Inhibitors Across Heart Failure Phenotypes: A Meta-Analysis. [PDF]

J Diabetes Res
A E ME, Ahmed AA.
europepmc   +1 more source

Response to the Letter to the Editor Entitled "SGLT2 Inhibitors in ADPKD: Time to Integrate Cardiovascular Outcomes". [PDF]

Kidney Int Rep
Uchiyama K.
europepmc   +1 more source